logo-loader
viewBio-Rad Laboratories

Bio-Rad Laboratories and Axis-Shield launch rheumatoid arthritis early detection test

blood_cells350_4b43066b49bff.jpg

Life science research and clinical diagnostics products manufacturer, Bio-Rad Laboratories, Inc (NYSE: BIO) and London listed in-vitro diagnostics (“IVD”) specialist, Axis-Shield (LSE: ASD) jointly announced this morning the launch of Bio-Rad’s BioPlex 2200 Anti CCP test for the early detection of rheumatoid arthritis.


The assa will run on Bio-Rad's BioPlex(R) 2200 system, measuring anti-cyclic citrullinated peptide (“CCP”) antibodies - a novel marker that has been shown to have “superior specificity” in the diagnosis of rheumatoid arthritis.


The BioPlex 2200 Anti-CCP kit is based on Axis-Shield's technology.


"The anti-CCP testing market is one of the fastest growing markets in autoimmune diagnostics," said John Goetz, Bio-Rad Vice President and Group Manager of Clinical Diagnostics. "The addition of this assay will add significantly to our growing menu of autoimmune tests on the BioPlex 2200 system."


"We are very pleased that Bio-Rad has reached this important commercial milestone in our agreement and believe that availability on the BioPlex system will help expand the market for this important early marker for this debilitating condition," said Ian Gilham, Axis-Shield CEO. "The measurement of these antibodies has recently been cited as a key parameter in the definitive diagnosis of rheumatoid arthritis by the influential American College of Rheumatology."


Initially the BioPlex 2200 Anti-CCP kit will be marketed in “certain countries” outside of the United States, as it is pending clearance by the FDA (Food & Drug Adminstration).

Quick facts: Bio-Rad Laboratories

Price: 477.66 USD

NYSE:BIO
Market: NYSE
Market Cap: $14.16 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Australian Vanadium confirms ‘exceptional’ vanadium extraction in test work

Australian Vanadium Ltd (ASX:AVL) (OTCMKTS:ATVVF) managing director Vincent Algar speaks to Proactive about recent pilot test-work conducted at the Australian Vanadium Project, which delivered leach extraction of up to 94.7%. The pilot-scale roast and leach testing has confirmed the...

1 day ago

2 min read